tirzepatide vs semaglutide diabetes versus Once Weekly in Patients with Type 2 | NEJM Tirzepatide vs semaglutide: A new

Maintenance Dosing & Continued Weight Management Objectives After completing the initial 8 weeks of weight management treatments, you and your provider will review your progress and long-term weight management goals

Developed by Novo Nordisk, this tablet is the first of its kind, providing an effective solution for enhancing blood sugar control alongside diet and exercise

One meta-analysis of 12 randomized controlled trials, with a total of over 11,700 patients, found that those taking tirzepatide experienced a greater reduction in their: Body mass index (BMI) Waist circumference Body weight The analysis found that tirzepatide had a dose-dependent effect, meaning that those taking higher doses lost more weight

SCFAs (especially butyrate and propionate) activate FFAR2/FFAR3 receptors on L-cells, stimulating GLP-1 secretion and improving appetite control

FDA Approval: Semaglutide is fully FDA-approved for weight management, while Tirzepatide is currently approved for diabetes treatment, with its weight-loss indication still pending

Some more conservative guides note several months to a few years depending on formulation and conditions